| | RedOrbit - Health - Aeolus Pharmaceuticals, Inc. Announces Capital Infusion From Existing Shareholders (Site not responding. Last check: 2007-10-31) |
 | | Commenting on the Aeolus Pipeline Initiative, Brian J. Day, Ph.D., a co- founder of Aeolus and co-inventor of its proprietary chemical compounds, and who serves as the Chief Science Officer to Aeolus, noted that "Aeolus has developed and tested approximately 200 proprietary catalytic antioxidant compounds over a ten year period. |
 | | In particular, Aeolus' catalytic antioxidants have been shown to significantly reduce tissue damage in animal models of ALS, stroke, chronic obstructive pulmonary disease, and mucositis caused by radiation therapy. |
 | | The initial therapeutic focus areas for the Aeolus Pipeline Initiative are: Parkinson's disease; Autoimmune disorders (arthritis and ulcerative colitis); Chronic Obstructive Lung Disease; Biodefense/Radioprotection; Tumor Suppression/Bone Marrow Transplantation; and Stroke. |
| www.redorbit.com /news/display?id=158375&source=r_health (740 words) |